14 studies found for:    Alzheimer | University of Utah
Show Display Options
Rank Status Study
1 Unknown  Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF;   Procedure: Placebo Surgery
2 Active, not recruiting Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Condition: Alzheimer's Disease
Interventions: Drug: Solanezumab;   Drug: Placebo
3 Completed
Has Results
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Drug: Placebo Control;   Drug: ELND005
4 Recruiting An Efficacy and Safety Study of LY3314814 in Early Alzheimer's Disease
Condition: Alzheimer´s Disease
Interventions: Drug: LY3314814;   Drug: Placebo
5 Terminated A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Bapineuzumab
6 Unknown  Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly
Condition: Alzheimer's Disease
Interventions: Radiation: 11C-PIB PET Scan;   Radiation: FDG-PET Scan
7 Completed Home-Based Assessment for Alzheimer Disease Prevention
Conditions: Mild Cognitive Impairment;   Alzheimer's Disease
Interventions: Behavioral: Mail and Live Phone;   Behavioral: Interactive Voice Response (IVR);   Behavioral: Home-based Computer Kiosk;   Behavioral: Traditional Evaluation Instruments
8 Recruiting 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Aducanumab (BIIB037);   Drug: Placebo
9 Completed Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
Condition: Alzheimer's Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Placebo Control;   Drug: Bapineuzumab 1.0 m/kg
10 Completed Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
Condition: Alzheimer's Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Placebo Control;   Drug: Bapineuzumab 1.0 m/kg
11 Enrolling by invitation Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
Condition: Alzheimer's Disease
Intervention: Drug: 18F-Flutemetamol
12 Recruiting Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)
Condition: Dementia
Intervention: Procedure: FDG-PET brain scan
13 Completed Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
Condition: Progressive Supranuclear Palsy
Interventions: Drug: Davunetide;   Drug: Placebo
14 Recruiting Cognitive Training and Practice Effects in MCI
Condition: Mild Cognitive Impairment
Intervention: Behavioral: computerized cognitive exercises

Indicates status has not been verified in more than two years